Soligenix Receives USAN Approval for “Hypericin Sodium” as Nonproprietary Name for Novel Active Ingredient in HyBryte™ and SGX302

PRINCETON, N.J., April 5, 2023 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the United…